Thierry Abribat, PhD, chief executive officer of Amolyt Pharma describes AZP-3601, a drug in development to treat hypoparathyroidism.  

Persons with hypoparathyroidism show abnormally low levels of calcium in the blood and high levels of phosphorus (hyperphosphatemia). 

Hypoparathyroidism is a deficiency of parathyroid hormone (PTH) that leads to decreased calcium and increased phosphorus levels in the blood.  This can lead to weakness, muscle cramps, excessive nervousness, headaches, and/or uncontrollable twitching and cramping spasms of certain muscles such as those of the hands, feet, arms, legs, and/or face (tetany). Numbness and tingling around the mouth, fingers, and toes may also occur. 

Hypoparathyroidism is usually due to damage to or removal of the parathyroid glands due to surgery for another condition, however other etiologies do exist. 

AZP-3601 targets the parathyroid hormone (PTH) receptor and as Dr. Arbribatt explains in this video, a phase 1 clinical trial has begun. 

For more information about this and other endocrine conditions, visit